Market Research Logo

Drugs and Diagnostics for Hematological Disorders: Global Markets

Drugs and Diagnostics for Hematological Disorders: Global Markets

The global market for hematology drugs and diagnostics is expected to grow from nearly $86.5 billion in 2015 to $124.3 billion in 2020 at a compound annual growth rate of 7.5% from 2015-2020.

This report provides:
An overview of the global market for drugs and diagnostics for hematological disorders.
Analyses of global market trends, with data from2015, and projections of CAGRs through 2020.
A breakdown of the market by hematological diseases, hematological cancers, and hematological diagnostics.
A review of blood cancers, such as various types of leukemia, lymphoma, and myeloma, and their therapies.
Evaluation of the market's dynamics, specifically growth drivers, restraints, and opportunities
Delineation of drugs approved by the FDA for hematological disorders.
Profiles of key companies in the industry.


The scope of this study covers instruments, reagents, testing, screening technology and the therapeutics markets for hematological disorders, including hemophilia and blood cancers. The report also discusses the regulatory environment, current technologies, new technologies, hematological disorders and cancer incidence, market projections and market share, along with latest trends, and clinical and new developments.

CHAPTER 1 INTRODUCTION
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THIS STUDY
INTENDED AUDIENCE
SCOPE OF THE STUDY
METHODOLOGY
INFORMATION SOURCES
ANALYST'S CREDENTIALS
RELATED BCC RESEARCH REPORTS
ABOUT BCC RESEARCH
CONDITIONS OF PURCHASE
ADDITIONAL COPIES
CUSTOM ANALYSES
BCC RESEARCH WEBSITE
DISCLAIMER
CHAPTER 2 SUMMARY
SUMMARY TABLE GLOBAL MARKET FOR HEMATOLOGY DRUGS AND DIAGNOSTICS, BY SEGMENT, THROUGH 2020 ($ MILLIONS)
SUMMARY FIGURE GLOBAL MARKET FOR HEMATOLOGY DRUGS AND DIAGNOSTICS, BY SEGMENT, 2012-2020 ($ MILLIONS)
CHAPTER 3 HEMATALOGICAL DISORDERS
TABLE 1 KEY BLOOD DISORDERS
TABLE 2 MALIGNANT BLOOD DISORDERS
TABLE 3 NONMALIGNANT BLOOD DISORDERS
BLOOD
TABLE 4 TYPE OF BLOOD CELLS AND FUNCTIONS
TABLE 5 COMPONENTS OF BLOOD
BLOOD DISORDERS/DISEASES
ANEMIA
Types of Anemia
TABLE 6 THREE MAJOR TYPES OF ANEMIA
TABLE 7 CAUSES OF ANEMIA
Symptoms
TABLE 8 SYMPTOMS OF ANEMIA
TABLE 9 ANEMIA: TYPES, CAUSES AND TREATMENT
MEGALOBLASTIC ANEMIAS
Cobalamin Deficiency
TABLE 10 DRUGS THAT CAN CAUSE COBALAMIN DEFICIENCY BY CLASS
Folate Deficiency
TABLE 11 DRUGS THAT CAN CAUSE FOLATE DEFICIENCY
Diagnostic Tests
Schilling Test
Serum Ferritin and Iron Studies
Other Tests
Treatment
HEMOGLOBIN DISORDERS
Categories
Thalassemia
Sickle Cell Anemia
TABLE 12 SICKLE CELL ANEMIA: KEY FACTS
Causes
World Health Organization's Resolutions
HEMOLYTIC ANEMIA
TABLE 13 LAB TESTS FOR ANEMIA
Treatment
Anemia Medications
PRIMARY THROMBOCYTHEMIA
Hemostasis: Steps of Mechanism
TABLE 14 HEMOSTASIS: THREE MAJOR STEPS
Types of Hemostasis
Hemostasis in Emergency Medicine
Artificial Hemostasis
TABLE 15 DRUGS THAT AFFECT THE ACTIVITY OF PLATELETS
TABLE 16 ANTICOAGULANTS THAT ACT ON THROMBIN
BLEEDING DISORDERS
TABLE 17 BLEEDING DISORDERS
TABLE 18 SYMPTOMS OF BLEEDING DISORDERS
TABLE 19 SIGNS AND TESTS FOR BLEEDING DISORDERS
Hemophilia
TABLE 20 KEY CHARACTERISTICS OF HEMOPHILIA
Classification
Historical Background
The Clotting Cascade
Hemorrhage
Natural Inhibitors
Acquired Hemophilia
Hemophilia Types
Symptoms and Complications
Diagnosis
Hemophilia and Bleeding
Genetic Testing
Treatment
TABLE 21 FVIII INHIBITORS
TABLE 22 MEDICATIONS FOR TREATING HEMOPHILIA
Factor VIII Products
TABLE 23 FACTOR VIII PRODUCTS
Antifibrinolytics
TABLE 24 ANTIFIBRINOLYTICS BY DRUG
Antihemophilic Agents
TABLE 25 ANTIHEMOPHILIC AGENTS BY CLASS
Coagulation Factor VIIa, Recombinants
Factor VIIa, Recombinant (NovoSeven)
Monoclonal Antibodies
Rituximab (Rituxan)
von Willebrand Disease
Symptoms and Diagnosis
Treatment
THROMBOPHILIA
Diagnosis and Treatment
THROMBOSIS
TABLE 26 FORMATION OF THROMBUS
Superficial Thrombophlebitis
DEEP VENOUS THROMBOSIS
Tests
Treatment
Surgery
HEREDITARY HEMORRHAGIC TELANGIECTASIA
ERYTHROCYTOSIS
Absolute Polycythemia
Types
Primary Polycythemia
Secondary Polycythemia
Chuvash Polycythemia
Relative Polycythemia
WHITE BLOOD CELL DISORDERS
Treatment
NEUTROPENIA
Causes
TABLE 27 CAUSES OF NEUTROPENIA
Symptoms and Diagnosis
Treatment
NEUTROPHILIA
BLOOD DISORDERS AFFECTING PLATELETS
TABLE 28 WHITE BLOOD CELL DISORDERS
Thrombocytopenia
Treatment
Lymphocytopenia
Treatment
Lymphocytic Leukocytosis
Monocytosis
Thrombocythemia and Thrombocytosis
Types
Primary Thrombocythemia
Secondary Thrombocytosis
TABLE 29 CAUSES OF SECONDARY THROMBOCYTOSIS
Symptoms
TABLE 30 DIAGNOSTIC TESTS FOR THROMBOCYTHEMIA
Treatment
TABLE 31 MEDICINES FOR THROMBOCYTHEMIA
Thrombocytopenia
Causes
TABLE 32 CAUSES OF THROMBOCYTOPENIA
RARE CONDITIONS THAT CAUSE BLOOD CLOTS
Signs and Symptoms
TABLE 33 SIGNS OF EXTERNAL BLEEDING
Tests
Treatment
SEVERE THROMBOCYTOPENIA
EOSINOPHILS AND DISORDERS
TABLE 34 COMMON DRUGS TO TREAT EOSINOPHILIA
BASOPHILIC DISORDERS
PLASMA CELL DISORDERS
CHAPTER 4 HEMATOLOGICAL CANCERS
TABLE 35 HEMATOLOGICAL CANCERS (BLOOD CANCERS)
CLASSIC CLASSIFICATION
TABLE 36 RELATIVE OCCURRENCE OF HEMATOLOGICAL MALIGNANCIES IN THE U.S., 2016 (NUMBER/%)
TABLE 37 TYPES OF HEMATOLOGICAL CANCERS
ACUTE MYELOID LEUKEMIA
CHRONIC MYELOID LEUKEMIA
ACUTE LYMPHOCYTIC LEUKEMIA
CHRONIC LYMPHOCYTIC LEUKEMIA
HODGKIN LYMPHOMA
NON-HODGKIN LYMPHOMA
Treatment and Side Effects
MULTIPLE MYELOMA
MYELODYSPLASTIC SYNDROME
Diagnosis
TABLE 38 FDA APPROVALS OF DRUGS FOR HEMATOLOGICAL DISORDERS/DISEASES, 2014-2016
TABLE 39 FDA APPROVALS OF DRUGS FOR HEMATOLOGICAL DISORDERS/DISEASES, 2012
TABLE 40 FDA APPROVALS OF DRUGS FOR HEMATOLOGICAL DISORDERS/DISEASES, 2011
TABLE 41 FDA APPROVALS OF DRUGS FOR HEMATOLOGICAL DISORDERS/DISEASES, 1996-2010
CHAPTER 5 LEUKEMIA
LYMPHOCYTIC LEUKEMIAS
MYELOGENOUS LEUKEMIAS
TABLE 42 TYPES OF LEUKEMIA
TABLE 43 TYPES OF LEUKEMIA AND KEY FEATURES
SYMPTOMS
CAUSES
DIAGNOSIS
TESTS
TABLE 44 DIAGNOSTIC EXAMS FOR LEUKEMIA
Complete Blood Count
White Cell Differential
Blood Smear
TABLE 45 ADDITIONAL TESTS
Fluorescence In Situ Hybridization (FISH)
Flow Cytometry
Immunophenotyping
Karyotype Test
Polymerase Chain Reaction
Bone Marrow Aspiration/Biopsy
Spinal Tap (Lumbar Puncture) and Cerebrospinal Fluid (CSF) Analysis
Immunophenotyping or Phenotyping by Flow Cytometry
Cytogenetics and Fluorescent In Situ Hybridization
Polymerase Chain Reaction (PCR)
TABLE 46 PCR TESTS
Non-Laboratory Tests
TABLE 47 NON-LABORATORY TESTS
TREATMENT
TABLE 48 COMMON TREATMENTS USED TO FIGHT LEUKEMIA
TABLE 49 NEWER CLASSES OF DRUGS
Drug Therapies for Blood Cancers
TABLE 50 ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT
TABLE 51 DRUGS APPROVED FOR ACUTE LYMPHOBLASTIC LEUKEMIA
TABLE 52 DRUGS APPROVED FOR CHRONIC LYMPHOCYTIC LEUKEMIA
TABLE 53 DRUGS APPROVED FOR ACUTE MYELOID LEUKEMIA
TABLE 54 DRUGS APPROVED FOR CHRONIC MYELOGENOUS
LEUKEMIA
Hairy Cell Leukemia: Treatment
T-CELL PROLYMPHOCYTIC LEUKEMIA
TABLE 55 T-CELL PROLYMPHOCYTIC LEUKEMIA: TREATMENT PLAN
JUVENILE MYELOMONOCYTIC LEUKEMIA
STAGES OF LEUKEMIA
TABLE 56 FACTORS AFFECTING LEUKEMIA STAGING AND PROGNOSIS
TREATMENTS AND DRUGS
Stem Cell Transplantation
Allogeneic Stem Cell Transplant
Autologous Stem Cell Transplant
Chemotherapy
Types of Chemotherapy for Leukemia
Chemotherapy for Acute Leukemias
Chemotherapy for Chronic Leukemias
TABLE 57 CHEMOTHERAPY DRUGS FOR CML
TABLE 58 CHEMOTHERAPY DRUGS FOR CLL
Intrathecal Chemotherapy
Targeted Drug Therapy for Leukemia
TABLE 59 TARGETED THERAPY DRUGS
Monoclonal Antibody Therapy
Radioimmunotherapy
TABLE 60 ADVANTAGES OF RADIOIMMUNOTHERAPY
Radiation Therapy
TABLE 61 COMMON RADIATION TREATMENTS: LEUKEMIA
External Beam Radiation Therapy
Total Body Irradiation
Total Marrow Irradiation
Nutrition Therapy after a Stem Cell Transplant
Managing Side Effects with Naturopathic Therapies
Pain Management for Leukemia
TABLE 62 PAIN MEDICATIONS
TABLE 63 EMERGING THERAPIES FOR LEUKEMIA
CONCLUSIONS
CHAPTER 6 LYMPHOMA
OVERVIEW
LYMPHOMA CAUSES
TABLE 64 CAUSES OF LYMPHOMA
CLASSIFICATION
TABLE 65 LYMPHOMA TYPES
STAGING
TABLE 66 STAGING FOR HL AND NHL TUMORS
NON-HODGKIN LYMPHOMA
TABLE 67 MATURE B-CELL NEOPLASMS
TABLE 68 MATURE T-CELL AND NATURAL KILLER CELL NEOPLASMS
TABLE 69 HODGKIN LYMPHOMA
TABLE 70 IMMUNODEFICIENCY-ASSOCIATED LYMPHOPROLIFERATIVE
DISORDERS
SIGNS AND SYMPTOMS
TABLE 71 SYMPTOMS OF NON-HODGKIN LYMPHOMA
TABLE 72 FIVE-YEAR RELATIVE SURVIVAL BY STAGE AT DIAGNOSIS: NON HODGKIN LYMPHOMA, 2006-2012 (%)
DIAGNOSIS AND TESTS
Biopsy
Imaging Studies
TABLE 73 IMAGING TESTS FOR LYMPHOMA
Bone Marrow Examination
Other Tests
Lumbar Puncture
Organ Function Tests
PROGNOSTIC FACTORS
TABLE 74 THE INTERNATIONAL PROGNOSTIC INDEX FOR HL
TABLE 75 THE INTERNATIONAL PROGNOSTIC INDEX FOR NHL
LYMPHOMA TREATMENT
RADIATION AND CHEMOTHERAPY
RADIATION THERAPY
CHEMOTHERAPY
BIOLOGICAL THERAPY
TABLE 76 PROMISING THERAPIES FOR TREATING LYMPHOMA
COMPLEMENTARY/ALTERNATIVE THERAPIES
CHAPTER 7 MULTIPLE MYELOMA
OVERVIEW
CAUSE
SYMPTOMS
COMPLICATIONS OF MYELOMA
Cryoglobulinemia
Amyloidosis
TYPES OF MYELOMA
INCIDENCE
DIAGNOSIS
TESTS
Prognostic Indicators
TABLE 77 PROGNOSTIC INDICATORS FOR MYELOMA
Bone Marrow Examination
TABLE 78 OTHER BONE MARROW TESTS
STAGING
Monoclonal Gammopathy of Undetermined Significance
Smoldering Multiple Myeloma
Indolent Multiple Myeloma
Symptomatic Multiple Myeloma
TABLE 79 MYELOMA: STAGING CRITERIA
TREATMENT AND PROGNOSIS
TABLE 80 MYELOMA'S RESPONSE TO TREATMENT
Myeloma Therapy
Chemotherapy
Radiation Therapy
Stem Cell Transplantation
Supportive Care
TABLE 81 SUPPORTIVE CARE FOR MYELOMA
OTHER DRUG THERAPIES
NEW DRUG THERAPIES
TABLE 82 DRUGS FOR MULTIPLE MYELOMA
TABLE 83 NEW AND EMERGING THERAPIES FOR MYELOMA
CONCLUSIONS
CHAPTER 8 MYELODYSPLASTIC SYNDROMES
TABLE 84 CHARACTERISTICS OF MDS
TABLE 85 CAUSES OF MDS
TABLE 86 MDS OR AML: THREE CATEGORIES
CLASSES OF MDS
TABLE 87 MYELODYSPLASTIC SYNDROMES: KEY FACTS
TABLE 88 FAB CLASSIFICATION OF MDS
TABLE 89 THE 2008 WHO CLASSIFICATION OF MDS
INTERNATIONAL PROGNOSTIC SCORING SYSTEM
TABLE 90 INTERNATIONAL PROGNOSTIC SCORING SYSTEM RISK
GROUPS AND PROGNOS (YEARS)
DIAGNOSIS AND TESTS
TABLE 91 CHANGES IN CELLS DUE TO MDS
PROGNOSIS AND TREATMENT OPTIONS
CHEMOTHERAPY
SUPPORTIVE CARE
DRUG PROFILES
EPOETIN ALFA (PROCRIT, EPOGEN)
DARBEPOETIN (ARANESP)
SARGRAMOSTIM (LEUKINE)
FILGRASTIM (NEUPOGEN)
DECITABINE (DACOGEN)
LENALIDOMIDE (REVLIMID)
VIDAZA (AZACITIDINE)
PREVIOUSLY TREATED MYELODYSPLASTIC SYNDROMES
CONCLUSIONS
CHAPTER 9 MYELOPROLIFERATIVE DISORDERS
TYPES OF CHRONIC MYELOPROLIFERATIVE DISORDERS
TABLE 92 CHRONIC MYELOPROLIFERATIVE DISORDERS
CLASSIFICATION: WHO
TABLE 93 CLASSIFICATION OF MYELOID NEOPLASMS ACCORDING TO THE 2008 WHO CLASSIFICATION SCHEME
TABLE 94 MYELOPROLIFERATIVE NEOPLASMS: KEY FACTS
STAGES OF CHRONIC MYELOPROLIFERATIVE DISORDERS
DIAGNOSIS
TESTS
TABLE 95 DIAGNOSTIC TESTS
TREATMENT
OTHER DRUG THERAPY
POLYCYTHEMIA VERA
OVERVIEW
TABLE 96 SYMPTOMS OF POLYCYTHEMIA VERA
CAUSES
RISK FACTORS
TABLE 97 BLOOD TESTS FOR POLYCYTHEMIA VERA
TREATMENT OF POLYCYTHEMIA VERA
Drugs for Treating Polycythemia Vera
TABLE 98 TREATMENT FOR POLYCYTHEMIA VERA
PROGNOSIS
COMPLICATIONS
Blood Clots
Enlarged Spleen (Splenomegaly)
Problems Due to High Levels of Red Blood Cells
OTHER BLOOD DISORDERS
CHRONIC IDIOPATHIC MYELOFIBROSIS
CAUSES
TABLE 99 CAUSATIVE FACTORS FOR MYELOFIBROSIS
TABLE 100 POTENTIAL COMPLICATIONS FROM MYELOFIBROSIS
PATHOGENESIS
DIAGNOSIS
TABLE 101 WHO DIAGNOSTIC CRITERIA FOR PMF
PROGNOSIS
TABLE 102 RISK FACTORS
SYMPTOMS
TABLE 103 IDIOPATHIC MYELOFIBROSIS AND SYMPTOMS
TABLE 104 PROGNOSIS FACTORS
TREATMENTS FOR MYELOFIBROSIS
TABLE 105 TREATMENT OF CHRONIC IDIOPATHIC MYELOFIBROSIS
Experimental Drug Therapy
Pomalidomide
TABLE 106 SOMATIC MUTATIONS
ESSENTIAL THROMBOCYTHEMIA
TABLE 107 CAUSES OF THROMBOCYTOSIS
Symptoms
TABLE 108 SYMPTOMS OF ESSENTIAL THROMBOCYTOSIS
Pathophysiology
Diagnosis
TABLE 109 ESSENTIAL THROMBOCYTHEMIA: DIAGNOSTIC CRITERIA
Treatment
Prognosis
Causes, Incidence and Risk Factors
Genes: Essential Thrombocythemia
Treatment of Essential Thrombocythemia
Diagnosis
TABLE 110 TREATMENT OF ET
Anti-platelet Treatment
ADP Receptor Antagonists
Platelet-Lowering Treatment
Anagrelide
Interferon-a (IFN-a)
ALTERNATIVE CYTOREDUCTIVE THERAPY
Pipobroman (PI)
Busulfan (BU)
Prognosis
Implication of the Description of JAK2 V617F Mutation on the Management of ET
CHRONIC NEUTROPHILIC LEUKEMIA
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA
TABLE 111 TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA
CHRONIC EOSINOPHILIC LEUKEMIA
TABLE 112 SYMPTOMS OF CHRONIC EOSINOPHILIC LEUKEMIA
TREATMENT OF CHRONIC EOSINOPHILIC LEUKEMIA
TABLE 113 TREATMENT OF CHRONIC EOSINOPHILIC LEUKEMIA
PIPELINE DRUGS
Incyte
Jakavi in Europe
SUMMARY
TABLE 114 CURRENT DRUGS
CHAPTER 10 EPIDEMIOLOGY OF HEMATOLOGICAL CANCERS
TABLE 115 CANCER KEY FACTS
TABLE 116 INCREASE IN CANCER BURDEN: FACTORS
INDIA
KENYA
WORLDWIDE INCIDENCE OF BLOOD CANCERS
TABLE 117 GLOBAL INCIDENCE OF BLOOD CANCERS, 2012 (NO./%)
TABLE 118 GLOBAL INCIDENCE OF BLOOD CANCERS, 2012 (NO.)
TABLE 119 GLOBAL INCIDENCE OF BLOOD CANCERS IN MEN, 2012 (NO./%)
TABLE 120 GLOBAL INCIDENCE OF BLOOD CANCERS IN WOMEN, 2012 (NO./%)
TABLE 121 TOP 10 COUNTRIES' CANCER INCIDENCE RATES (PER 100,000
POPULATION)
BLOOD CANCER INCIDENCE IN THE UNITED STATES
TABLE 122 ESTIMATED INCIDENCE OF BLOOD CANCERS IN THE U.S., 2011 VS. 2016 (PER 100,000 POPULATION)
FIGURE 1 ESTIMATED INCIDENCE OF BLOOD CANCERS, IN THE U.S., 2011 VS. 2016 (PER 100,000 POPULATION)
TABLE 123 ESTIMATED NEW CASES OF LEUKEMIA, LYMPHOMA AND MYELOMA IN THE U.S., 2016 (NO.)
FIGURE 2 ESTIMATED NEW CASES OF LEUKEMIA, LYMPHOMA AND MYELOMA IN THE U.S., 2016 (NO.)
TABLE 124 ESTIMATED LEUKEMIA AND LYMPHOMA INCIDENCE AND DEATHS IN THE U.S., 2016 (NO.)
FIGURE 3 ESTIMATED LEUKEMIA AND LYMPHOMA INCIDENCE AND DEATHS IN THE U.S., 2016 (NO.)
DEATHS FROM BLOOD CANCERS
LEUKEMIA
NUCLEAR REACTORS AND BLOOD CANCERS
SIGNS AND SYMPTOMS
LEUKEMIA IN CHILDREN AND ADOLESCENTS
GLOBAL INCIDENCE
TABLE 125 GLOBAL INCIDENCE OF LEUKEMIA, 2012 (NUMBER/%)
LEUKEMIA IN THE UNITED STATES
TABLE 126 U.S. LEUKEMIA INCIDENCE STATISTICS, 2012
TABLE 127 ESTIMATED NEW CASES OF LEUKEMIA AND DEATHS IN THE U.S., 2010-2016 (NO.)
FIGURE 4 ESTIMATED NEW CASES OF LEUKEMIA AND DEATHS IN THE U.S., 2010-2016 (NO.)
TABLE 128 ESTIMATED NEW CASES OF LEUKEMIA IN ADULTS AND CHILDREN IN THE U.S., 2016
TABLE 129 ESTIMATED PREVALENCE OF DIFFERENT TYPES OF LEUKEMIA IN THE U.S., 2008 (NO.)
FIGURE 5 ESTIMATED PREVALENCE OF DIFFERENT TYPES OF LEUKEMIA IN THE U.S., 2008 (NO.)
Leukemia in Children and Adolescents
TABLE 130 PREVALENCE OF LEUKEMIA IN THE U.S., 2016 (NO.)
FIGURE 6 PREVALENCE OF LEUKEMIA IN THE U.S., 2016 (NO.)
Adolescents and Young Adults
Adults
TABLE 131 TYPES OF LEUKEMIA IN ADULTS IN THE U.S. AND AGE GROUP
TABLE 132 ESTIMATED LEUKEMIA INCIDENCE AND DEATHS IN THE U.S. BY TYPE, 2012 (NO.)
FIGURE 7 ESTIMATED LEUKEMIA INCIDENCE AND DEATHS IN THE U.S. BY TYPE, 2012 (NO.)
TABLE 133 AGE-ADJUSTED INCIDENCE RATES OF LEUKEMIA IN THE U.S. BY RACE, SEER 18, 2009-2013 (PER 100,000 POPULATION)
Survival
TABLE 134 FIVE-YEAR RELATIVE SURVIVAL RATES IN THE U.S. FOR LEUKEMIA, 2005-2011 (%)
TABLE 135 ESTIMATED DEATHS FROM LEUKEMIA IN THE U.S., 2016 (NO).
FIGURE 8 ESTIMATED DEATHS FROM LEUKEMIA IN THE U.S., 2016 (NO).
LEUKEMIA INCIDENCE IN THE UNITED KINGDOM
TABLE 136 NEW CASES OF LEUKEMIA IN THE U.K., 2013 (NO.)
Cause
WORLDWIDE MORTALITY RATES: LEUKEMIA
TABLE 137 GLOBAL ESTIMATES OF LEUKEMIA DEATHS/MORTALITY RATES, 2012
LYMPHOMA
SIGNS AND SYMPTOMS
POSSIBLE CAUSES
TREATMENT
WORLDWIDE INCIDENCE OF NHL
TABLE 138 GLOBAL ESTIMATED INCIDENCE RATES OF NON-HODGKIN LYMPHOMA FOR ALL AGES AND BOTH SEXES, 2012
TABLE 139 GLOBAL ESTIMATED NON-HODGKIN LYMPHOMA MORTALITY RATES BY ALL AGES AND BOTH SEXES, 2012
GLOBAL INCIDENCE OF HODGKIN'S LYMPHOMA
TABLE 140 GLOBAL ESTIMATED INCIDENCE OF HODGKIN LYMPHOMA FOR ALL AGES AND BOTH SEXES, 2012
CANADA: LYMPHOMA
EUROPEAN UNION
Non-Hodgkin's Lymphoma
TABLE 141 ESTIMATED INCIDENCE OF NON-HODGKIN LYMPHOMA IN EU-27 COUNTRIES BY GENDER, 2008 (AGE-STANDARDIZED RATES
PER 100,000 POPULATION)
FIGURE 9 ESTIMATED INCIDENCE OF NON-HODGKIN LYMPHOMA IN EU-27 COUNTRIES BY GENDER, 2008 (AGE-STANDARDIZED RATES
PER 100,000 POPULATION)
TABLE 142 ESTIMATED NON-HODGKIN LYMPHOMA MORTALITY RATES IN EU-27 COUNTRIES BY GENDER, 2008 (AGE-STANDARDIZED RATES
PER 100,000 POPULATION)
FIGURE 10 ESTIMATED NON-HODGKIN LYMPHOMA MORTALITY RATES IN EU-27 COUNTRIES BY GENDER, 2008 (AGE-STANDARDIZED RATES
PER 100,000)
Hodgkin Lymphoma in EU: 2012
TABLE 143 ESTIMATED HODGKIN LYMPHOMA INCIDENCE AND MORTALITY RATES IN EU-27 COUNTRIES, 2012 (ESTIMATED
RATES PER 100,000 POPULATION)
FIGURE 11 ESTIMATED HODGKIN LYMPHOMA INCIDENCE AND MORTALITY RATES IN EU-27 COUNTRIES, 2012 (ESTIMATED
RATES PER 100,000 POPULATION)
LYMPHOMA IN THE UNITED STATES
New Cases
TABLE 144 ESTIMATED LYMPHOMA INCIDENCE AND DEATHS IN THE U.S., 2016 (NO.)
FIGURE 12 ESTIMATED LYMPHOMA INCIDENCE AND DEATHS IN THE U.S., 2016 (NO.)
TABLE 145 ESTIMATED LYMPHOMA INCIDENCE AND DEATHS IN THE U.S., 2011-2012 (NO.)
FIGURE 13 ESTIMATED LYMPHOMA INCIDENCE AND DEATHS IN THE U.S., 2011-2012 (NO.)
TABLE 146 ESTIMATED NEW CASES OF LYMPHOMA IN THE U.S. BY TYPE, 2011-2016 (NO.)
FIGURE 14 ESTIMATED NEW CASES OF LYMPHOMA IN THE U.S. BY TYPE, 2011-2016 (NO.)
TABLE 147 ESTIMATED NEW CASES OF LYMPHOMA IN THE U.S. BY TYPE AND GENDER, 2012 (NO.)
FIGURE 15 ESTIMATED NEW CASES OF LYMPHOMA IN THE U.S. BY TYPE AND GENDER, 2012 (NO.)
TABLE 148 ESTIMATED DEATHS FROM LYMPHOMA IN THE U.S. BY TYPE AND GENDER, 2011 (NO.)
FIGURE 16 ESTIMATED DEATHS FROM LYMPHOMA IN THE U.S. BY TYPE AND GENDER, 2011 (NO.)
TABLE 149 U.S. AGE-SPECIFIC NHL INCIDENCE RATES BY GENDER (ESTIMATED RATES PER 100,000 POPULATION)
TABLE 150 U.S. LYMPHOMA INCIDENCE RATES BY RACE, 2005-2009 (PER 100,000 POPULATION)
TABLE 151 U.S. LYMPHOMA MORTALITY RATES BY RACE, 2005-2009 (PER 100,000 POPULATION)
Race and Ethnicity
Children
Adolescents and Young Adults
Adults
Survival
TABLE 152 STAGE DISTRIBUTION AND FIVE-YEAR RELATIVE SURVIVAL OF ALL RACES, BOTH SEXES BY STAGE AT DIAGNOSIS, 2002-2008 (%)
LYMPHOMA IN THE UNITED KINGDOM
TABLE 153 NEW CASES OF NON-HODGKIN LYMPHOMA IN THE U.K., 2013 (NO.)
TABLE 154 NON-HODGKIN LYMPHOMA DEATHS IN THE U.K. BY SEX, 2012 (NO.)
Hodgkin Lymphoma in the United Kingdom
TABLE 155 ESTIMATED NUMBER OF NEW CASES OF HODGKIN LYMPHOMA IN THE U.K., 2013 (NO.)
TABLE 156 ESTIMATED NUMBER OF DEATHS FROM HODGKIN'S LYMPHOMA IN THE U.K., 2012 (NO.)
FIGURE 17 ESTIMATED NUMBER OF DEATHS FROM HODGKIN’S LYMPHOMA IN THE U.K., 2012 (NO.)
MYELOMA
SYMPTOMS
MYELOMA INCIDENCE WORLDWIDE
TABLE 157 ESTIMATED GLOBAL INCIDENCE OF MYELOMA, 2008 (RATES PER 100,000 POPULATION)
FIGURE 18 ESTIMATED GLOBAL INCIDENCE OF MYELOMA, 2008 (RATES PER 100,000 POPULATION)
TABLE 158 ESTIMATED GLOBAL MYELOMA MORTALITY RATES BY REGION, 2008 (PER 100,000 POPULATION)
FIGURE 19 ESTIMATED GLOBAL MYELOMA MORTALITY RATES BY REGION, 2008 (PER 100,000 POPULATION)
MYELOMA IN EUROPEAN UNION COUNTRIES
TABLE 159 ESTIMATED INCIDENCE OF MYELOMA IN EU-27 COUNTRIES, 2012 (NO.)
TABLE 160 DEATHS FROM MYELOMA IN EU-27 COUNTRIES, 2012 (NO.)
MYELOMA IN THE UNITED STATES
TABLE 161 ESTIMATED MYELOMA INCIDENCE AND DEATHS IN THE U.S., 2011-2016 (NO.)
FIGURE 20 ESTIMATED MYELOMA INCIDENCE AND DEATHS IN THE U.S., 2011-2016 (NO.)
TABLE 162 ESTIMATED INCIDENCE OF MYELOMA BY GENDER IN THE U.S., 2011-2016 (NO.)
FIGURE 21 ESTIMATED INCIDENCE OF MYELOMA BY GENDER IN THE U.S., 2011-2016 (NO.)
TABLE 163 AGE-ADJUSTED INCIDENCE RATES OF MYELOMA IN THE U.S. BY RACE, SEER 18 2009-2013 (PER 100,000 POPULATION)
TABLE 164 AGE-ADJUSTED DEATH RATES FROM MYELOMA IN THE U.S. BY RACE, SEER 18 2009-2013 (PER 100,000 POPULATION)
Survival
TABLE 165 DISTRIBUTION AND FIVE-YEAR RELATIVE SURVIVAL FOR ALL AGES AND BOTH SEXES IN THE U.S. BY STAGE AT DIAGNOSIS, 2002-2008 (%)
MYELOMA IN THE UNITED KINGDOM
TABLE 166 NEW CASES OF MYELOMA IN THE U.K., 2013 (NO.)
TABLE 167 MYELOMA DEATHS IN THE U.K., 2012 (NO.)
CONCLUSIONS
MYELODYSPLASTIC SYNDROMES
SIGNS AND SYMPTOMS
TABLE 168 ESTIMATED NEW CASES OF MDS IN THE U.S., 2012 (NO.)
RACE AND ETHNICITY
BLOOD DISEASES AND INCIDENCE
ANEMIA
SICKLE CELL ANEMIA
THALASSEMIA
BLEEDING DISORDERS
HEMOPHILIA
Worldwide Incidence of Hemophilia
Mortality/Morbidity
Hemophilia in the United States
CLOTTING DISORDERS
CHAPTER 11 HEMATOLOGY INSTRUMENTS AND REAGENTS: A GLOBAL
MARKET PERSPECTIVE
HEMATOLOGICAL MALIGNANCIES
MARKET DYNAMICS: HEMATOLOGY INSTRUMENTS AND REAGENTS
TABLE 169 KEY FACTORS DRIVING THE GROWTH OF THE HEMATOLOGICAL
DISORDERS MARKET
TABLE 170 GLOBAL HEMATOLOGY INSTRUMENTS AND REAGENTS MARKET, THROUGH 2020 ($ MILLIONS)
FIGURE 22 GLOBAL HEMATOLOGY INSTRUMENTS AND REAGENTS MARKET, 2012-2020 ($ MILLIONS)
GLOBAL MARKET
Market Drivers
TABLE 171 KEY HEMATOLOGY PRODUCTS
Key Players in Hematology Instruments
TABLE 172 GLOBAL MAJOR COMPANIES IN THE HEMATOLOGY
MARKET
Key Company Profiles
Roche
Sysmex
Flow Cytometers
TABLE 173 KEY PLAYERS IN FLOW CYTOMETRY
TABLE 174 GLOBAL FLOW CYTOMETRY INSTRUMENTS AND REAGENTS MARKET, THROUGH 2020 ($ MILLIONS)
FIGURE 23 GLOBAL FLOW CYTOMETRY INSTRUMENTS AND REAGENTS MARKET, 2012-2020 ($ MILLIONS)
TABLE 175 MAJOR FLOW CYTOMETRY APPLICATIONS
Coagulation Analyzers
TABLE 176 CELL ANALYZERS
Future Outlook
HEMATOLOGY TEST PRODUCTS AND MARKET
TABLE 177 HEMATOLOGY TESTS
COMPLETE BLOOD COUNT (CBC)
TABLE 178 COMPLETE BLOOD COUNT: COMPONENTS MEASURED
MAJOR ROUTINE AND SPECIAL HEMATOLOGY TESTS
Partial Thromboplastin Time
Total Serum Protein
Chemistry Panel
TABLE 179 TESTS INCLUDED IN A CHEMISTRY SCREEN
TABLE 180 CHEMISTRY SCREEN
Vitamin B12
The Cold Agglutinins Test
Prothrombin
Reticulocyte
Urine Cytology
TABLE 181 URINE TESTS AND APPLICATIONS
BLOOD PROTEIN TESTING
TUMOR MARKER TESTS
IN VITRO DIAGNOSTIC MARKET
TABLE 182 GLOBAL IVD PRODUCTS MARKET, THROUGH 2020 ($ MILLIONS)
FIGURE 24 GLOBAL IVD PRODUCTS MARKET, 2012-2020 ($ MILLIONS)
TABLE 183 U.S. IVD MARKET, THROUGH 2020 ($ MILLIONS)
FIGURE 25 U.S. IVD MARKET, 2012-2020 ($ MILLIONS)
Immunoassays
TABLE 184 GLOBAL MARKET FOR IMMUNOASSAY SYSTEMS, THROUGH 2020 ($ MILLIONS)
FIGURE 26 GLOBAL MARKET FOR IMMUNOASSAY SYSTEMS, 2012-2020 ($ MILLIONS)
Market Trends
TABLE 185 GLOBAL MARKET FOR ENZYME IMMUNOASSAY SYSTEMS, THROUGH 2020 ($ MILLIONS)
FIGURE 27 GLOBAL MARKET FOR ENZYME IMMUNOASSAY SYSTEMS, 2015-2020 ($ MILLIONS)
TABLE 186 KEY PLAYERS IN THE IMMUNOASSAYS MARKET
Molecular Diagnostics
TABLE 187 GLOBAL MOLECULAR DIAGNOSTICS MARKET, THROUGH 2020 ($ MILLIONS)
FIGURE 28 GLOBAL MOLECULAR DIAGNOSTICS MARKET, 2015-2020 ($ MILLIONS)
TABLE 188 MAJOR PLAYERS IN MOLECULAR DIAGNOSTICS MARKET POINT-OF-CARE MARKET
TABLE 189 GLOBAL POINT-OF-CARE TESTING MARKET, THROUGH 2020 ($ MILLIONS)
FIGURE 29 GLOBAL POINT-OF-CARE TESTING MARKET, 2015-2020 ($ MILLIONS)
TABLE 190 POC TESTING KITS
POC Tests
TABLE 191 GLOBAL MARKET FOR POC TESTS, THROUGH 2020 ($ MILLIONS)
FIGURE 30 GLOBAL MARKET FOR POC TESTS, 2015-2020 ($ MILLIONS)
POC Immunoassays
TABLE 192 GLOBAL POINT-OF-CARE IMMUNOASSAY MARKET, THROUGH 2020 ($ MILLIONS)
FIGURE 31 GLOBAL POINT-OF-CARE IMMUNOASSAY MARKET, 2015-2020 ($ MILLIONS)
Cardiac Markers
TABLE 193 TYPES OF CARDIAC MARKERS
POC Market Penetration
Future Outlook
BLOOD TRANSFUSION DIAGNOSTIC AND BLOOD SCREENING MARKET
TABLE 194 KEY MARKET PLAYERS IN THE BLOOD SCREENING MARKET
CONCLUSIONS
CHAPTER 12 GLOBAL MARKET FOR TREATMENTS FOR HEMATOLOGICAL
DISORDERS
THERAPEUTIC DRUG MARKET
TABLE 195 GLOBAL MARKET FOR TREATMENTS FOR HEMATOLOGICAL DISORDERS, BY TYPE, THROUGH 2020 ($ MILLIONS)
FIGURE 32 GLOBAL MARKET FOR TREATMENTS FOR HEMATOLOGICAL DISORDERS, BY TYPE, 2012-2020 ($ MILLIONS)
TABLE 196 GLOBAL MARKET SHARES OF TREATMENTS FOR HEMATOLOGICAL DISORDERS BY TYPE, 2015 AND 2020 (%)
KEY MARKET PLAYERS
TABLE 197 PATENT EXPIRIES OF MAJOR BLOCKBUSTERS DRUGS
TABLE 198 GLOBAL KEY PLAYERS OF HEMATOLOGICAL DISORDERS MARKET BY PRODUCTS AND MARKET SHARE, 2015 (%)
TABLE 199 MARKET DRIVERS OF HEMATOLOGICAL DISORDERS
TABLE 200 MARKET RESTRAINTS OF HEMATOLOGICAL DISORDERS
ANEMIA TREATMENT MARKET
TABLE 201 GLOBAL ANEMIA TREATMENT MARKET, THROUGH 2020 ($ MILLIONS)
FIGURE 33 GLOBAL ANEMIA TREATMENT MARKET, 2012-2020 ($ MILLIONS)
TABLE 202 TYPES OF ANEMIA
Anemia Treatments
TABLE 203 COMMON ANEMIA TREATMENTS
TABLE 204 ERYTHROPOIETIN STIMULATING AGENTS
Aranesp
TABLE 205 KEY ANEMIA DRUGS SALES, 2012 AND 2015 ($ MILLIONS)
FIGURE 34 KEY ANEMIA DRUGS SALES, 2012 AND 2015 ($ MILLIONS)
Epogen
Procrit
Costs
NeoRecormon
TABLE 206 GLOBAL NEORECORMON MARKET, 2010-2015* ($ MILLIONS)
FIGURE 35 GLOBAL NEORECORMON MARKET, 2010-2015* ($ MILLIONS)
TABLE 207 GLOBAL NEORECORMON MARKET, 2009 ($ MILLIONS)
Biosimilars
TABLE 208 BIOSIMILARS OF EPOETIN ALFA AND DARBEPOETIN
ALFA
Medicare and Anemia Drug Usage
Market Trends
Drug Profiles
Promacta (Eltrombopag)
Roxadustat
Peginesatide
Future Strategies
Major Players
GlaxoSmithKline and Bayer
FibroGen
Stanford
Ligand
Pluristem Therapeutics
AMAG Pharma
Akebia Therapeutics
TABLE 209 AKEBIA THERAPEUTICS: ANEMIA DRUG IN DEVELOPMENT-AKB-6548
THROMBOSIS TREATMENT MARKET
TABLE 210 GLOBAL ANTITHROMBOTIC DRUG MARKET, BY TYPE, THROUGH 2020 ($ MILLIONS)
FIGURE 36 GLOBAL ANTITHROMBOTIC DRUG MARKET, BY TYPE, 2012-2020 ($ MILLIONS)
TABLE 211 LEADING DRUGS IN THE ANTITHROMBOTIC AGENTS MARKET
Anticoagulant Market
TABLE 212 GLOBAL ANTICOAGULANT DRUG MARKET, THROUGH 2020 ($ MILLIONS)
FIGURE 37 GLOBAL ANTICOAGULANT DRUG MARKET, 2012-2020 ($ MILLIONS)
Oral Anticoagulants
Injectable Anticoagulants
Development of New Drugs and Market
Antiplatelet Market
TABLE 213 GLOBAL ANTIPLATELET DRUG MARKET, THROUGH 2020 ($ MILLIONS)
FIGURE 38 GLOBAL ANTIPLATELET DRUG MARKET, 2012-2020 ($ MILLIONS)
Drug Profiles
Plavix
Generic Versions of Clopidogrel
Plavix: History
Plavix Market Trends
TABLE 214 SOME COMMON ANTIPLATELET AND
ANTICOAGULANT
Effient/Efient
Competition in the Antiplatelet Market
TABLE 215 GLOBAL ANTIPLATELET DRUGS MARKET, THROUGH 2020 ($ MILLIONS)
TABLE 216 U.S. SALES OF PLAVIX, 2012 ($ MILLIONS)
Drug Profiles
Brilinta
Edoxaban/Savaysa/Lixiana
Semuloparin
Lovenox/Enoxaparin
Generic Lovenox
TABLE 217 GLOBAL ANTITHROMBOTIC AGENTS MARKET, THROUGH 2020 ($ MILLIONS)
Lovenox History
New Drugs
Kengrexal
Zontivity
Market Dynamics
Anticoagulant Market
Drug Profiles
Eliquis
Xarelto
TABLE 218 XARELTO: APPROVALS IN VENOUS ARTERIAL
THROMBOEMBOLIC INDICATIONS
Pradaxa
Arixtra
Activase
TABLE 219 GLOBAL ACTIVASE MARKET, THROUGH 2020 ($ MILLIONS)
Angiomax
Market Trends for Anticoagulants
Warfarin
PLATELET AGGREGATION INHIBITORS AND MARKET IMPACT
TABLE 220 KEY PLATELET AGGREGATION INHIBITOR DRUG MARKET, 2012 AND 2015 ($ MILLIONS)
TABLE 221 PLATELET AGGREGATION INHIBITORS: PIPELINE DRUGS
Cangrelor
Heparin Market and Market Dynamics
TABLE 222 KEY PLAYERS IN THE GLOBAL HEPARIN MARKET
TABLE 223 THROMBOSIS MARKET: PIPELINE DRUGS
TABLE 224 PLATELET INHIBITOR: PIPELINE DRUGS
NEUTROPENIA TREATMENT MARKET
TABLE 225 GLOBAL NEUTROPENIA DRUG MARKET, THROUGH 2020 ($ MILLIONS)
FIGURE 39 GLOBAL NEUTROPENIA DRUG MARKET, 2012-2020 ($ MILLIONS)
TABLE 226 COMPANY MARKET SHARES OF KEY NEUTROPENIA DRUGS, 2015 (%)
Neulasta (Pegfilgrastim) and Neupogen (Filgrastim)
TABLE 227 GROWTH FACTORS FOR TREATING NEUTROPENIA
TABLE 228 GLOBAL NEULASTA/NEUPOGEN MARKET, 2012 AND 2015 ($ MILLIONS)
TABLE 229 GLOBAL SARGRAMOSTIM MARKET, 2010 ($ MILLIONS)
Filgrastim Biosimilars
TABLE 230 COMPANIES WITH SHORT-ACTING FILGRASTIMS IN PHASE III CLINICAL DEVELOPMENT IN EUROPE
TABLE 231 FILGRASTIM PRODUCTS
Teva Pharmaceutical
Competition in the Neutropenia Market
HEMOPHILIA MARKET
TABLE 232 GLOBAL HEMOPHILIA THERAPEUTICS MARKET, THROUGH 2020 ($ MILLIONS)
FIGURE 40 GLOBAL HEMOPHILIA THERAPEUTICS MARKET, 2012-2020 ($ MILLIONS)
New Products
TABLE 233 GLOBAL KEY HEMOPHILIA PLAYERS
Gene Therapy
Drugs for the Hemophilia Market
TABLE 234 KEY HEMOPHILIA DRUGS
TABLE 235 GLOBAL MARKET FOR RECOMBINANT COAGULATION FACTORS FOR HEMOPHILIA, BY TYPE, 2010 ($ MILLIONS)
FIGURE 41 GLOBAL MARKET FOR RECOMBINANT COAGULATION FACTORS FOR HEMOPHILIA, BY TYPE, 2010 ($ MILLIONS)
Market Barriers
Drug Pipeline
TABLE 236 OTHER COAGULATION PRODUCTS
Bayer
TABLE 237 GENE THERAPY PROGRAMS IN HEMOPHILIA
Other Molecules
TABLE 238 FDA APPROVED DRUGS FOR HEMATOLOGY, AUG. 2013-MARCH 2016
Advate
Biogen Idec
Blood Disorders Pipeline
TABLE 239 APPROVALS BY HEALTH CANADA, MARCH 2014-JAN. 2016
CONCLUSIONS
CHAPTER 13 HEMATOLOGICAL CANCER THERAPIES MARKET
OVERVIEW
TABLE 240 CANCER IN THE UNITED STATES
HEMATOLOGICAL CANCERS DRUG MARKET
CLASSIFICATION OF HEMATOLOGIC MALIGNANCIES
CHRONIC MYELOID DISORDERS
GLOBAL CYTOTOXIC THERAPIES MARKET
TABLE 241 CYTOTOXIC THERAPIES MARKET INDICATIONS
TABLE 242 LIST OF MEDICATIONS
TABLE 243 GLOBAL CYTOTHERAPEUTICS MARKET, 2010 AND 2017 ($ MILLIONS)
FIGURE 42 GLOBAL CYTOTHERAPEUTICS MARKET, 2010 AND 2017 ($ MILLIONS)
U.S. CYTOTHERAPEUTICS MARKET
TABLE 244 U.S. CYTOTHERAPEUTICS MARKET, 2012 AND 2017 ($ MILLIONS)
FIGURE 43 U.S. CYTOTHERAPEUTICS MARKET, 2012 AND 2017 ($ MILLIONS)
EUROPEAN CYTOTHERAPEUTICS MARKET
TABLE 245 EUROPEAN CYTOTHERAPEUTICS MARKET, 2012 AND 2017 ($ MILLIONS)
FIGURE 44 EUROPEAN CYTOTHERAPEUTICS MARKET, 2012 AND 2017 ($ MILLIONS)
JAPANESE CYTOTHERAPEUTICS MARKET
TABLE 246 JAPANESE CYTOTHERAPEUTICS MARKET, 2012 AND 2017 ($ MILLIONS)
FIGURE 45 JAPANESE CYTOTHERAPEUTICS MARKET, 2012 AND 2017 ($ MILLIONS)
LEUKEMIA MARKET AND CHALLENGES
TABLE 247 MAJOR LEUKEMIA PLAYERS
IS THERE AN UNMET NEED?
TABLE 248 RECENT LEUKEMIA INCIDENCE PERCENTAGE BY CATEGORY
(%)
TABLE 249 GLOBAL LEUKEMIA MARKET, BY TYPE, THROUGH 2020 ($ MILLIONS)
FIGURE 46 GLOBAL LEUKEMIA MARKET, BY TYPE, 2012-2020 ($ MILLIONS)
GLOBAL LEUKEMIA MARKET
TABLE 250 LEUKEMIA MARKET SHARE FORECAST, BY COUNTRY, 2011 (%)
U.S. Leukemia Market
TABLE 251 U.S. LEUKEMIA MARKET, THROUGH 2020 ($ MILLIONS)
FIGURE 47 U.S. LEUKEMIA MARKET, 2012-2020 ($ MILLIONS)
European Leukemia Market
TABLE 252 EUROPEAN LEUKEMIA MARKET, THROUGH 2020 ($ MILLIONS)
FIGURE 48 EUROPEAN LEUKEMIA MARKET, 2012-2020 ($ MILLIONS)
Japanese Leukemia Market
TABLE 253 JAPAN'S LEUKEMIA MARKET, THROUGH 2020 ($ MILLIONS)
FIGURE 49 JAPAN'S LEUKEMIA MARKET, 2012-2020 ($ MILLIONS)
TABLE 254 GLOBAL LEUKEMIA MARKET BY REGION, THROUGH 2020
($ MILLIONS)
FIGURE 50 GLOBAL LEUKEMIA MARKET BY REGION, 2012-2020 ($ MILLIONS)
CHRONIC MYELOGENOUS LEUKEMIA MARKET
TABLE 255 GLOBAL CHRONIC MYELOGENOUS LEUKEMIA MARKET, THROUGH 2020 ($ MILLIONS)
FIGURE 51 GLOBAL CHRONIC MYELOGENOUS LEUKEMIA MARKET, 2012-2020 ($ MILLIONS)
MARKET TRENDS AND THERAPEUTIC DRUGS
TABLE 256 DRUG CLASSES' FOR LEUKEMIA DRUG DEVELOPMENT
TABLE 257 KEY CHRONIC MYELOGENOUS LEUKEMIA MARKET, BY DRUG, 2010-2015 ($ MILLIONS)
FIGURE 52 KEY CHRONIC MYELOGENOUS LEUKEMIA MARKET, BY DRUG, 2010-2015 ($ MILLIONS)
Market Trends
Therapeutic Drugs
Gleevec
TABLE 258 KEY CML MEDICINES AND COST
TABLE 259 GLEEVAC FDA APPROVALS, 2002-2012
Tasigna
Sprycel
Combination Treatment
New Drugs for CML
Drug Profiles
Bosulif
Synribo
Bafetinib
Rebastinib/DCC-2036
Danusertib
TABLE 260 RECENT PIPELINE DRUGS FOR LEUKEMIA
Ponatinib
ACUTE LYMPHOCYTIC LEUKEMIA MARKET
TABLE 261 GLOBAL ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET, THROUGH 2020 ($ MILLIONS)
FIGURE 53 GLOBAL ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET, 2012-2020 ($ MILLIONS)
TABLE 262 MAJOR ACUTE LYMPHOCYTIC LEUKEMIA PLAYERS IN THE MARKET
ACUTE LYMPHOCYTIC LEUKEMIA AND CHILDREN
THERAPEUTICS
TABLE 263 DRUGS FOR ACUTE LYMPHOCYTIC LEUKEMIA (ALL)
TREATMENT
Clolar
Oncaspar
Nelarabine
Marqibo
TABLE 264 APPROVED DRUGS FOR ALL
Graspa
ACUTE MYELOID LEUKEMIA (AML) MARKET
TABLE 265 GLOBAL ACUTE MYELOID LEUKEMIA MARKET, THROUGH 2020 ($ MILLIONS)
FIGURE 54 GLOBAL ACUTE MYELOID LEUKEMIA MARKET, 2012-2020 ($ MILLIONS)
THERAPEUTIC DRUGS
Elacytarabine
Quizartinib
KEY COMPANIES
TABLE 266 KEY COMPANIES IN THE AML MARKET
NEW DEVELOPMENTS
Astex Pharmaceuticals
ACUTE MYELOID LEUKEMIA AND CHILDREN
Treatment Costs
CHRONIC LYMPHOCYTIC LEUKEMIA MARKET
TABLE 267 GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA MARKET, THROUGH 2020 ($ MILLIONS)
FIGURE 55 CHRONIC LYMPHOCYTIC LEUKEMIA MARKET, 2012-2020 ($ MILLIONS)
THERAPEUTIC DRUGS
Arzerra
TABLE 268 GLOBAL ARZERRA MARKET, 2010-2015 ($ MILLIONS)
Fludara
Campath
Treanda
TABLE 269 GLOBAL TREANDA MARKET, 2014-2017 ($ MILLIONS)
PIPELINE
Venetoclax
NOX-A12 anti-CXCL12/SDF-1/Spiegelmer
TABLE 270 NOX-A12: HOW DOES IT WORK?
Imbruvica/Ibrutinib
Idelalisib/GS-1101
TABLE 271 GILEAD: HEMATOLOGY AND ONCOLOGY PIPELINE
NEW DEVELOPMENTS
Blinatumomab
NEW DRUGS IN DEVELOPMENT
Combining the Targeted Drugs with Other Treatments
NEW DRUGS FOR CML
CANCER VACCINES
LYMPHOMA DRUG MARKET
MARKET TRENDS
TABLE 272 GENERIC DRUGS USED IN COMBINATION TO TREAT
HODGKIN LYMPHOMA
TABLE 273 DRUGS USED IN COMBINATION TO TREAT NON-HODGKIN
LYMPHOMA
CHEMOTHERAPY
BONE MARROW AND PERIPHERAL BLOOD STEM CELL TRANSPLANTS
TARGETED THERAPIES
Antibiotics
Monoclonal Antibodies
Lymphoma Vaccines
Idelalisib
NON-HODGKIN LYMPHOMA DRUG MARKET
TABLE 274 GLOBAL NON-HODGKIN LYMPHOMA DRUG MARKET, THROUGH 2020 ($ MILLIONS)
FIGURE 56 GLOBAL NON-HODGKIN LYMPHOMA DRUG MARKET, 2012-2020 ($ MILLIONS)
Rituximab
TABLE 275 GLOBAL RITUXIMAB MARKET, 2010-2015 ($ MILLIONS)
Rituxan Biosimilars Development and Key Companies
TABLE 276 RITUXAN: BIOSIMILARS IN DEVELOPMENT
New Drugs
Revlimid
TABLE 277 GLOBAL REVLIMID MARKET, 2011-2015 ($ MILLIONS)
HODGKIN LYMPHOMA TREATMENT MARKET
TABLE 278 GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET, THROUGH 2020 ($ MILLIONS)
FIGURE 57 GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET, 2012-2020 ($ MILLIONS)
Market Dynamics and Pipeline
Adcetris/Brentuximab Vedotin
Farydak/Panobinostat
MULTIPLE MYELOMA TREATMENT MARKET
TABLE 279 GLOBAL MULTIPLE MYELOMA TREATMENT MARKET, THROUGH 2020 ($ MILLIONS)
FIGURE 58 GLOBAL MULTIPLE MYELOMA TREATMENT MARKET, 2012-2020 ($ MILLIONS)
TABLE 280 DRUGS FOR THE MYELOMA MARKET
THERAPEUTIC DRUGS
Kyprolis
Revlimid
Velcade
Pomalidomide
PIPELINE DRUG CANDIDATES
TABLE 281 PIPELINE DRUGS FOR MYELOMA IN DEVELOPMENT
Obatoclax
Perifosine
Panobinostat (Faridak)
Aplidin
Treanda
TABLE 282 TREANDA CLINICAL TRIALS IN RELAPSED AND/OR REFRACTORY MYELOMA
MYELODYSPLASTIC SYNDROME MARKET
TABLE 283 GLOBAL MYELODYSPLASTIC SYNDROME MARKET, THROUGH 2020 ($ MILLIONS)
FIGURE 59 GLOBAL MYELODYSPLASTIC SYNDROME MARKET, 2012-2020 ($ MILLIONS)
MDS THERAPIES
TABLE 284 APPROVED DRUGS FOR THE TREATMENT OF MDS
Decitabine
Vidaza
PIPELINE
TABLE 285 DRUGS IN CLINICAL DEVELOPMENT
MYELOPROLIFERATIVE DISORDERS
TABLE 286 GLOBAL MYELOPROLIFERATIVE DISORDERS MARKET, THROUGH
2020 ($ MILLIONS)
FIGURE 60 GLOBAL MYELOPROLIFERATIVE DISORDERS MARKET, 2012-2020 ($ MILLIONS)
MARKET TRENDS
TABLE 287 JAK2 INHIBITORS IN DEVELOPMENT
THERAPEUTIC DRUGS
Jakafi/Ruxolitinib
TABLE 288 GLOBAL JAKAFI/RUXOLITINIB MARKET, THROUGH 2020 ($ MILLIONS)
TG101348
AZD1480
R723
XL019
CYT387
SB1518
MARKET FOR ESSENTIAL THROMBOCYTOSIS (ET)
MYELOFIBROSIS MARKET
TABLE 289 GLOBAL MYELOFIBROSIS MARKET, THROUGH 2020 ($ MILLIONS)
FIGURE 61 GLOBAL MYELOFIBROSIS MARKET, 2012-2020 ($ MILLIONS)
TREATMENT OPTIONS FOR MYELOFIBROSIS
POLYCYTHEMIA VERA (PV) THERAPEUTICS MARKET
TABLE 290 GLOBAL POLYCYTHEMIA VERA MARKET, THROUGH 2020 ($ MILLIONS)
FIGURE 62 GLOBAL POLYCYTHEMIA VERA MARKET, 2012-2020 ($ MILLIONS)
TREATMENT EXPENSE
CHAPTER 14 PATENT LANDSCAPE AND CURRENT DEVELOPMENTS
TABLE 291 MAJOR BLOOD DISORDER DRUG PATENT EXPIRIES, 2009-2015
TABLE 292 KEY BLOOD DISORDER DRUGS: PATENT EXPIRY
TABLE 293 DRUGS LOSING PATENT PROTECTION BY 2015, GLOBAL SALES 2010 ($ MILLIONS)
HEMATOLOGICAL CANCER DRUG PATENT EXPIRIES
TABLE 294 BIOLOGIC DRUG PATENT EXPIRIES
NEW APPROVALS
TABLE 295 NEW DRUG APPROVALS FOR BLOOD DISORDERS, 2012 NEW HEMATOLOGICAL CANCER DRUGS
TABLE 296 NEW DRUG APPROVALS FOR HEMATOLOGICAL CANCERS, 2012
NEWS AND DEVELOPMENTS
Type 2 Diabetes Linked to Increased Blood Cancer Risk
NOVARTIS AND PATENT ISSUES
DRUGS IN DEVELOPMENT
Ariad Pharmaceuticals
Pharmacyclics
AiCuris
Cell Therapeutics
Biogen Idec/Swedish Orphan Biovitrum
Inspiration Biopharmaceuticals
Novartis
Merck
The Medicines Co.
Isis Pharmaceuticals
CytoPharm and Amarillo Biosciences
SuppreMol
MorphoSys and Xencor
ARIAD Pharmaceuticals
OTHER DEVELOPMENTS
Universal Cancer Blood Test
Boehringer Ingelheim
Janssen Biotech
Mergers
Blood Disorders News
AMAG Pharmaceuticals
Affymax vs. Amgen
ACQUISITIONS
Gilead Sciences
CHAPTER 15 SELECTED COMPANY PROFILES
ABBOTT LABORATORIES
ABON PHARMACEUTICALS
AMBIT BIOSCIENCES
AMGEN
AMPHASTAR PHARMACEUTICALS
ARIAD PHARMACEUTICALS
ASTELLAS PHARMA US
ASTEX PHARMACEUTICALS
ASTRAZENECA
BAXALTA INC.
BAXTER HEALTHCARE CORP.
BAYER HEALTHCARE PHARMACEUTICALS
BIOGEN IDEC
BOEHRINGER INGELHEIM GMBH
BRISTOL-MYERS SQUIBB
CELGENE CORP.
CHUGAI PHARMACEUTICAL
C.R. BARD
CZ BIOMED CORP.
DAIICHI SANKYO CO. LTD.
DECIPHERA PHARMACEUTICALS
DIAGNOCURE
EISAI INC.
ELI LILLY AND CO.
ENZON PHARMACEUTICALS
ERYTECH PHARMA SA
EXELIXIS
GE HEALTHCARE
GENENTECH INC.
GENMAB INC.
GILEAD SCIENCES
GLAXOSMITHKLINE
HOLOGIC
HORIBA LTD.
JOHNSON & JOHNSON
THE MEDICINES CO.
MEDKOO BIOSCIENCES
MOMENTA PHARMACEUTICALS
NOXXON PHARMA AG
PORTOLA PHARMACEUTICALS INC.
OPKO HEALTH
OTSUKA PHARMACEUTICAL
PFIZER
PHARMACYCLICS
ROCHE DIAGNOSTICS
SANDOZ INTERNATIONAL GMBH
SANOFI
SIEMENS AG
SPECTRUM PHARMACEUTICALS
TEVA PHARMACEUTICAL INDUSTRIES LTD.
WATSON PHARMACEUTICALS INC.
YM BIOSCIENCES INC.
CHAPTER 16 BIBLIOGRAPHY

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report